Literature DB >> 31566843

Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.

C Terzi1, M Bingul1, N C Arslan2, E Ozturk3, A E Canda1, O Isik3, T Yilmazlar3, F Obuz4, I Birkay Gorken5, M Kurt6, M Unlu7, N Ugras8, O Kanat9, I Oztop10.   

Abstract

AIM: The aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer.
METHOD: This was a randomized trial which included a total of 330 patients from two institutions. Patients with locally advanced (T3-4N0M0, TxN+M0) rectal cancer were randomized into 8- and 12-week interval groups. All the patients received long-course CRT (45 Gy in 1.8 Gy fractions and concomitant oral capecitabine or 5-fluorouracil infusion). Surgery was performed at either 8 or 12 weeks after CRT. The primary end-point was pCR. Secondary end-points were sphincter preservation, postoperative morbidity and mortality.
RESULTS: Two-hundred and fifty-two patients (n = 125 in the 8-week group, n = 127 in the 12-week group) were included. Demographic and clinical characteristics were similar between groups. The overall pCR rate was 17.9% (n = 45): 12% (n = 15) in the 8-week group and 23.6% (n = 30) in the 12-week group (P = 0.021). Sphincter-preserving surgery was performed in 107 (85.6%) patients which was significantly higher than the 94 (74%) patients in the 12-week group (P = 0.016). Postoperative mortality was seen in three (1.2%) patients overall and was not different between groups (1.6% in 8 weeks vs 0.8% in 12 weeks, P = 0.494). Groups were similar in anastomotic leak (10.8% in 8 weeks vs 4.5% in 12 weeks, P = 0.088) and morbidity (30.4% in 8 weeks and 20.1% in 12 weeks, P = 0.083).
CONCLUSION: Extending the interval between CRT and surgery from 8 to 12 weeks resulted in a 2-fold increase in pCR rate without any difference in mortality and morbidity. Colorectal Disease
© 2019 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Rectal cancer; complete response; interval; neoadjuvant chemoradiotherapy

Year:  2019        PMID: 31566843     DOI: 10.1111/codi.14867

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.

Authors:  Erhan Akgun; Cemil Caliskan; Osman Bozbiyik; Tayfun Yoldas; Basak Doganavsargil; Serdar Ozkok; Timur Kose; Bulent Karabulut; Nevra Elmas; Omer Ozutemiz
Journal:  BJS Open       Date:  2022-09-02

2.  Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses.

Authors:  Miao Yu; Deng-Chao Wang; Sheng Li; Li-Yan Huang; Jian Wei
Journal:  Int J Colorectal Dis       Date:  2022-03-12       Impact factor: 2.571

3.  Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Chun-Ming Huang; Ming-Yii Huang; Ching-Wen Huang; Hsiang-Lin Tsai; Wei-Chih Su; Wei-Chiao Chang; Jaw-Yuan Wang; Hon-Yi Shi
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

4.  Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.

Authors:  Yinkui Wang; Zining Liu; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Ziyu Li; Jiafu Ji
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

5.  Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer.

Authors:  Jiawei Chen; Hongsheng Deng; Jiaxi He; Zhufeng Wang; Shuben Li
Journal:  Front Oncol       Date:  2022-09-07       Impact factor: 5.738

6.  Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.

Authors:  Kendrick Koo; Rachel Ward; Ryan L Smith; Jeremy Ruben; Peter W G Carne; Hany Elsaleh
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.